Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Align, Angelalign, Art-Islets, Austrianova, Avant, Cellcarta, Lunit, Qurient, ...
Genmab A/S is paying $8 billion to acquire Merus NV, gaining rights to the latter’s phase III-stage petosemtamab, a ...
Rhythm Diagnostic Systems SAS (RDS) raised €14 million (US$16.6 million) in a series A funding round for Multisense, its ...
Up to 71% of people carry at least one pathogenic variant that could contribute to development of a heritable disorder in ...
Bar what it described as a “placebo wobble,” Moonlake Therapeutics AG turned in positive results from the phase III trials of ...
In August 2025, BioWorld logged 95 clinical trial updates across phases I to III, compared to 140 tracked in July and 254 in ...
The U.K. National Institute for Health and Care Excellence unveiled a plan that is designed to provide less cumbersome market ...
Simcere Zaiming Pharmaceutical Co. Ltd. has obtained IND clearance by the FDA for SIM-0609, a CDH17-targeting antibody-drug ...
Around the globe, fungal infections affect more than 1 billion people and account for several million deaths every year. They ...
Sovargen Co. Ltd. inked a $550 million license deal with Angelini Pharma SpA, granting Angelini development and commercialization rights to SVG-105 (paxalisib/SIM-0395), an oral small-molecule drug ...
Enanta Pharmaceuticals Inc.’s phase IIb study of zelicapavir missed its primary endpoint in treating respiratory syncytial virus (RSV) but mined enough positive results to get the company to talk ...
Bard Peripheral Vascular Inc., agreed to pay $7.2 million to settle allegations that two photoplethysmography products it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback